6/16/2025

Janusmed kön och genus

Janusmed kön och genus – Oxaliplatin Pfizer

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Oxaliplatin

Oxaliplatin

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs. 2003;14(10):817-24.

  2. Kim J, Ji E, Jung K, Jung IH, Park J, Lee JC et al. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. J Pers Med. 2021;11(2):.

  3. Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017;12(9):e0183288.

  4. Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2014;44(1):319-26.

  5. Pan X, Xiao X, Ding Y, Shu Y, Zhang W, Huang L. Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system. Front Pharmacol. 2024;15:1431579.

  6. Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J et al. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol. 2006;23(3):347-57.

  7. Suzuki A, Kobayashi R, Fujii H, Iihara H, Takahashi T, Yoshida K et al. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk. Anticancer Res. 2016;36(12):6527-6533.

  8. Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology. 2009;76(4):231-8.

  9. Oxaliplatin Accord (oxaliplatin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-11-04, cited 2025-05-19]

  1. Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs. 2003;14(10):817-24.
  2. Kim J, Ji E, Jung K, Jung IH, Park J, Lee JC et al. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. J Pers Med. 2021;11(2):.
  3. Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017;12(9):e0183288.
  4. Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2014;44(1):319-26.
  5. Pan X, Xiao X, Ding Y, Shu Y, Zhang W, Huang L. Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system. Front Pharmacol. 2024;15:1431579.
  6. Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J et al. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol. 2006;23(3):347-57.
  7. Suzuki A, Kobayashi R, Fujii H, Iihara H, Takahashi T, Yoshida K et al. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk. Anticancer Res. 2016;36(12):6527-6533.
  8. Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology. 2009;76(4):231-8.
  9. Oxaliplatin Accord (oxaliplatin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-11-04, cited 2025-05-19]